Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of Phase I and II trials

Replication-selective viral agents hold promise as a novel cancer treatment platform (virotherapy). dl1520 (Onyx-015, now CI-1042, Pfizer Corp., Groton, CT, USA), an E1B-55kD gene-deleted adenovirus, was the first such genetically engineered agent to be tested in humans. Over 250 cancer patients have now been treated on approximately ten clinical trials (phase I-III). The virus was generally well tolerated at doses of up to 2 x 1012 particles by intratumoural, intraperitoneal, hepatic arterial and iv. administration; no maximally-tolerated doses were identified following intra-vascular administration. Viral replication was tumour-selective and was documented after administration by all routes; however, viral replication was variable depending on tumour histology. Single agent efficacy has been relatively limited to date (0 - 14% local tumour regression rates). In combination with chemotherapy, however, encouraging antitumoural activity has been demonstrated. These clinical research results demonstrate the potential of this novel treatment platform, as well as the hurdles to be overcome. Novel replication-selective agents with improved potency are being developed.

[1]  J. Hecht,et al.  A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  M. Lemmon,et al.  Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  F. Khuri,et al.  Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. , 2000, Cancer research.

[4]  B. Hann,et al.  Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015) , 2000, Nature Medicine.

[5]  L. Johnson,et al.  An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy , 2000, Nature Medicine.

[6]  I. Tannock,et al.  A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer , 2000, Nature Medicine.

[7]  Nahum Sonenberg,et al.  Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus , 2000, Nature Medicine.

[8]  L. Eisenlohr,et al.  Poxvirus vectors: orphaned and underappreciated. , 2000, The Journal of clinical investigation.

[9]  D. Kirn.  Replication-selective microbiological agents: fighting cancer with targeted germ warfare. , 2000, The Journal of clinical investigation.

[10]  D. Kirn,et al.  Replication-selective adenoviruses as oncolytic agents. , 2000, The Journal of clinical investigation.

[11]  M. Gulley,et al.  A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  D. Kirn,et al.  In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. , 2000, Cancer research.

[13]  T. McDonnell,et al.  A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo , 2000, Oncogene.

[14]  I. Ganly,et al.  p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy , 2000, British Journal of Cancer.

[15]  I. Kovesdi,et al.  Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. , 1999, Science.

[16]  A. Berk,et al.  p53-Independent and -Dependent Requirements for E1B-55K in Adenovirus Type 5 Replication , 1999, Journal of Virology.

[17]  D. Kirn,et al.  Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. , 1999, Cancer research.

[18]  O. Wildner,et al.  Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. , 1999, Cancer research.

[19]  Samuel I. Miller,et al.  Lipid A mutant Salmonella with suppressed virulence and TNFα induction retain tumor-targeting in vivo , 1999, Nature Biotechnology.

[20]  A. Hengstermann,et al.  Replication of ONYX-015, a Potential Anticancer Adenovirus, Is Independent of p53 Status in Tumor Cells , 1998, Journal of Virology.

[21]  F. Goodrum,et al.  p53 Status Does Not Determine Outcome of E1B 55-Kilodalton Mutant Adenovirus Lytic Infection , 1998, Journal of Virology.

[22]  M. Coffey,et al.  Reovirus therapy of tumors with activated Ras pathway. , 1998, Science.

[23]  Anthony R. Hall,et al.  p53-dependent cell death/apoptosis is required for a productive adenovirus infection , 1998, Nature Medicine.

[24]  J. H. Kim,et al.  A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. , 1998, Human gene therapy.

[25]  J. Pawelek,et al.  Tumor-targeted Salmonella as a novel anticancer vector. , 1997, Cancer research.

[26]  A. Levine,et al.  Nuclear export of the E1B 55‐kDa and E4 34‐kDa adenoviral oncoproteins mediated by a rev‐like signal sequence , 1997, The EMBO journal.

[27]  D. Kirn,et al.  ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents , 1997, Nature Medicine.

[28]  F. Goodrum,et al.  The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle , 1997, Journal of virology.

[29]  A. Fattaey,et al.  An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells , 1996, Science.

[30]  N. Horikoshi,et al.  Blockage by Adenovirus E4orf6 of Transcriptional Activation by the p53 Tumor Suppressor , 1996, Science.

[31]  R. Tripp,et al.  The role of human adenovirus early region 3 proteins (gp19K, 10.4K, 14.5K, and 14.7K) in a murine pneumonia model , 1996, Journal of virology.

[32]  L. Eisenlohr,et al.  In situ cytokine gene transfection using vaccinia virus vectors. , 1996, Seminars in oncology.

[33]  R. Martuza,et al.  Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas , 1995, Nature Medicine.

[34]  M. Peeples,et al.  Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. , 1994, Cancer research.

[35]  J. Park,et al.  Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. , 1994, Cancer research.

[36]  W. Wold,et al.  Adenovirus proteins that subvert host defenses. , 1994, Trends in microbiology.

[37]  R. Martuza,et al.  Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. , 1994, Cancer research.

[38]  Gooding Lr.  Regulation of TNF-mediated cell death and inflammation by human adenoviruses. , 1994 .

[39]  L. Gooding.  Regulation of TNF-mediated cell death and inflammation by human adenoviruses. , 1994, Infectious agents and disease.

[40]  A. Berk,et al.  Adenovirus E1B oncoprotein tethers a transcriptional repression domain to p53. , 1994, Genes & development.

[41]  D. Larsimont,et al.  Parvovirus H‐1 inhibits growth of short‐term tumor‐derived but not normal mammary tissue cultures , 1993, International journal of cancer.

[42]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[43]  K. Münger,et al.  The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[44]  D M Coen,et al.  Experimental therapy of human glioma by means of a genetically engineered virus mutant , 1991, Science.

[45]  A. Berk,et al.  Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. , 1987, Virology.

[46]  T. Asada.  Treatment of human cancer with mumps virus , 1974, Cancer.

[47]  H. H. King.  Viruses in Treatment of Cancer , 1958, British medical journal.

[48]  R. Huebner,et al.  Studies on the use of viruses in the treatment of carcinoma of the cervix , 1956 .